Effectiveness of the inactivated

CoronaVac vaccine against SARS-

CoV-2 in Chile
Preliminary report

Presented by: Dr. Rafael Araos

Advisor to the Undersecretariat of Public Health
Researcher Universidad del Desarrollo

April 16th 2021

 Symptomatic cases
Casos Sintomáticos

2000
4000
6000

0
feb/17
mar/02
mar/16
mar/30
abr/13
abr/27
may/11
may/25
jun/08
jun/22
jul/06
jul/20
ago/03
Observed

ago/17
observados

ago/31
STATUS OF SARS-COV-2 IN CHILE

sep/14
sep/28
imputados

oct/12
Attributed

oct/26
Fecha de Inicio de los Síntomas

nov/09
Date of onset of symptoms

nov/23
estimados
Estimated

dic/07
dic/21
ene/04
ene/18
feb/01
feb/15
mar/01
mar/15
mar/29
abr/12
abr/26
2
STATUS OF SARS-COV-2 IN CHILE
Evolution
Evolución deincidence rate per every
la tasa de incidencia 100100
por cada thousand people
mil habitantes
SegúnBygrupo
age group
de edad

Incidence rate
Age

Notification epidemiological week

3
 Number
Número of Defunciones
de deaths

100
200
300

0
mar/09
mar/23
abr/06
abr/20
may/04
may/18
jun/01
jun/15
jun/29
jul/13
jul/27
ago/10
Observed

ago/24
STATUS OF SARS-COV-2 IN CHILE

sep/07
Observado

sep/21
Date of death oct/05
oct/19
nov/02
Fecha de Defunción
Estimado

nov/16
Estimated

nov/30
dic/14
dic/28
ene/11
ene/25
feb/08
feb/22
mar/08
mar/22
abr/05
abr/19
4
PROGRESS OF THE SARS-COV-2 IMMUNIZATION SCHEDULE

SARS-CoV-2 Vaccination Campaign. Country wide

(Number of vaccines administered)

Number of People vaccinated with People vaccinated with Target population to Vaccination coverage
administered doses 1 dose 2 doses be vaccinated (people with 1 and 2 doses)
12,726,959 7,600,908 5,126,051 15,200,840 33.7%

Region % of people with 1 and 2 doses

5
AVANCE DEL PROGRAMA DE INMUNIZACIÓN CONTRA SARS-COV-2

9.9%
Pfizer-BioNTech

33.7%
of the target population has
been fully vaccinated
90.1%
CoronaVac

6
CASES IN TIME
Evolution of new cases (2021)
Indexed to 100 by 02/03/2021 for each age group
00 to 39 years old 50 to 59 years old
40 to 49 years old
New cases (7-day moving average)

60 to 69 years old 70 to 79 years old 80 years old and older

Notification date
7
HOSPITAL ADMISSIONS IN TIME
Evolution of new admissions to any type of bed (2021)
Indexed to 100 by 02/03/2021 for each age group
New admissions to any type of bed (7-day moving average)

00 to 39 years old 50 to 59 years old

40 to 49 years old

60 to 69 years old 70 to 79 years old 80 years old and older

Admission date
8
ICU ADMISSIONS IN TIME
Evolution of new admissions to ICU (2021)
Indexed to 100 by 02/03/2021 for each age group
00 to 39 years old 50 to 59 years old
40 to 49 years old
New admissions to ICU (7-day moving average)

60 to 69 years old 70 to 79 years old 80 years old and older

Admission date
9
DEATHS DUE TO COVID-19 IN TIME
Evolution of new deaths (2021)
Indexed to 100 by 02/03/2021 for each age group
00
00to
to39
39years
yearsold
old 50
50to
to59
59years
yearsold
old
40
40to
to49
49years
yearsold
old
New deaths (7-day moving average)

60
60to
to69
69years
yearsold
old 70
70to
to79
79years
yearsold
old 80
80years
yearsold
old and
andolder
older

Date of death
10
PRELIMINARY EFFECTIVENESS OF CORONAVAC

› vCOVID cohort Chile ~10,500,000 individuals (>16 years) under the National Health Fund (FONASA)
› Compares outcomes between people vaccinated by CoronaVac® or unvaccinated (02/02/2021 –
04/01/2021) adjusted by age, gender, region of residence, income level, and nationality
• Outcomes
- Covid-19 symptomatic (cases confirmed by RT-PCR or antigen test for SARS-CoV-2)
- Hospital admissions
- ICU admissions
- Deaths due to Covid-19 (U07.1)
› Groups to be compared
• Unvaccinated
• Partially vaccinated (≥14 days after the first dose)
• Fully vaccinated (≥ 14 days after the second dose)
• The period between days 0 – 13 after the first or second doses were not considered (“unknown”
state of immunity)

11
 RESULTS

EFFECTIVENESS OF CORONAVAC®
14 DAYS AFTER THE SECOND DOSE

67% 85% 89% 80%

(65% - 69%) (83% - 87%) (84% - 92%) (73% - 86%)
Effectiveness to prevent Effectiveness to prevent
Effectiveness to prevent Effectiveness to prevent
Symptomatic Covid-19 Hospital admission ICU admission Death

12
EFFECTIVNESS OF CORONAVAC (1 and 2 doses)

13
WHAT SHOULD WE UNDERSTAND BY EFFECTIVENESS?

It is the protection provided by a vaccine under real-life conditions

What do results tell us?
• Effectiveness of 67% to prevent Covid-19
⁻ Out of 100 people who could have had Covid-19, there would have only been
33 cases, if we are all vaccinated.

• Effectiveness of 80% to prevent deaths due to Covid-19

› Out of 100 people who could have died from Covid-19, 20 would actually do, if
we are all vaccinated.

14
SYMPTOMATIC CASES

Cumulative incidence (%)

Time since full vaccination (days)

15
SYMPTOMATIC CASES

Cumulative incidence (%)

Time since full vaccination (days)

16
HOSPITAL ADMISSIONS

Cumulative incidence (%)

Time since full vaccination (days)

17
HOSPITAL ADMISSIONS

Cumulative incidence (%)

Time since full vaccination (days)

18
ICU ADMISSION CASES

Cumulative incidence (%)

Time since full vaccination (days)

19
ICU ADMISSION CASES

Cumulative incidence (%)

Time since full vaccination (days)

20
CONFIRMED DEATHS

Cumulative incidence (%)

Time since full vaccination (days)

21
CONFIRMED DEATHS

Cumulative incidence (%)

Time since full vaccination (days)

22
CONCLUSIONS

› In a scenario of high epidemic activity), the vaccine studied protects susceptible

groups (the elderly and people with comorbidities) against symptomatic SARS-CoV-2
infection, as well as against the most severe forms of the disease.

› Since we do not have 100%-effective vaccines, it is essential that we ALL get.

› No se deben descuidar las medidas de salud pública adicionales a la inmunización.

• Hygiene and personal care, mobility restrictions

**This is a preliminary report and it will be updated on a monthly basis**

23
ACKNOWLEDGEMENTS

› Team at the Ministry of Health

• National Immunization Program (PNI)
• Health Planning Division, Epidemiology Department, Health Statistics and Information
Department
• National Health Fund (FONASA)
• Public Helth Institute (ISP)
• Primary Healthcare Division (DIVAP)

› Academic Team
• School of Medicine Clínica Alemana - Universidad del Desarrollo
• Pontificia Universidad Católica de Chile

› Covid-19 Advisory Council

24
25
26
27
28